Stock 1784 BIONET CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BIONET Corp.

Equities

1784

TW0001784007

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
65.5 TWD -1.21% Intraday chart for BIONET Corp. -1.80% +12.74%
03-19 BIONET Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 BIONET Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,310 1,925 1,920 1,880 2,063 2,737
Enterprise Value (EV) 1 896.4 1,542 1,544 1,511 1,640 1,875
P/E ratio 53.9 x 290 x 151 x 70.7 x 54.9 x 35 x
Yield 1.06% 0.32% 0.45% 1.23% 1.59% 1.22%
Capitalization / Revenue 1.7 x 2.48 x 2.38 x 2.04 x 2.1 x 2.43 x
EV / Revenue 1.16 x 1.99 x 1.91 x 1.64 x 1.67 x 1.66 x
EV / EBITDA 14.7 x 44.4 x 66 x 27.4 x 19.7 x 17.2 x
EV / FCF -2,991 x 71.9 x 37.4 x -151 x 26.6 x 26.7 x
FCF Yield -0.03% 1.39% 2.67% -0.66% 3.76% 3.74%
Price to Book 1.15 x 1.8 x 1.79 x 1.72 x 1.91 x 2.31 x
Nbr of stocks (in thousands) 49,627 47,483 47,513 47,475 46,993 47,117
Reference price 2 26.40 40.55 40.40 39.60 43.90 58.10
Announcement Date 29/03/19 30/03/20 30/03/21 31/03/22 31/03/23 19/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 770.6 775.6 806.6 921.4 980.4 1,127
EBITDA 1 60.96 34.7 23.41 55.17 83.41 109.1
EBIT 1 34.23 8.19 -3.808 31.21 56.82 84.69
Operating Margin 4.44% 1.06% -0.47% 3.39% 5.8% 7.51%
Earnings before Tax (EBT) 1 45.79 25.76 6.422 41.19 70.46 107.1
Net income 1 24.23 6.803 12.74 26.62 37.97 78.4
Net margin 3.14% 0.88% 1.58% 2.89% 3.87% 6.95%
EPS 2 0.4900 0.1400 0.2682 0.5600 0.8000 1.660
Free Cash Flow 1 -0.2998 21.44 41.31 -10.01 61.69 70.21
FCF margin -0.04% 2.76% 5.12% -1.09% 6.29% 6.23%
FCF Conversion (EBITDA) - 61.78% 176.51% - 73.96% 64.38%
FCF Conversion (Net income) - 315.14% 324.26% - 162.47% 89.56%
Dividend per Share 2 0.2800 0.1300 0.1800 0.4858 0.6965 0.7100
Announcement Date 29/03/19 30/03/20 30/03/21 31/03/22 31/03/23 19/03/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 414 384 375 369 423 862
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.3 21.4 41.3 -10 61.7 70.2
ROE (net income / shareholders' equity) 2.75% 1.57% 0.1% 2.51% 4.06% 5.34%
ROA (Net income/ Total Assets) 1.19% 0.29% -0.14% 1.11% 1.96% 2.53%
Assets 1 2,044 2,356 -9,361 2,401 1,937 3,101
Book Value Per Share 2 22.90 22.50 22.60 23.00 23.00 25.10
Cash Flow per Share 2 2.000 1.660 2.690 2.550 3.440 5.040
Capex 1 16.6 11.6 26.8 10.2 28.9 20
Capex / Sales 2.16% 1.5% 3.33% 1.1% 2.95% 1.78%
Announcement Date 29/03/19 30/03/20 30/03/21 31/03/22 31/03/23 19/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIONET CORP. Stock BIONET Corp.
+12.74% 95.54M
MODERNA, INC. Stock Moderna, Inc.
+26.37% 48.16B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.01% 41.73B
LONZA GROUP AG Stock Lonza Group AG
+42.83% 41.03B
CELLTRION, INC. Stock Celltrion, Inc.
-5.31% 28.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.34% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.69% 18.96B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.23% 12.92B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.99% 12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.38% 11.77B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 1784 Stock
  4. Financials BIONET Corp.